Educational information
This video was recorded at the ESC in Paris, France, on September 1, 2019.
Faculty
Daniel Thuijs, MD works as a PhD-fellow at the Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands
Disclosures
his recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Overview
ESC 2019 Thuijs presents the results of the SYNTAX Extended Survival trial. Compared to PCI, CABG did not significantly lower all-cause death in patients with three-vessel disease or left main CAD at 10 year follow-up.
